FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000248717> ?p ?o ?g. }

• W2000248717 endingPage "613" @default.
• W2000248717 startingPage "605" @default.
• W2000248717 abstract "1. Draflazine, a nucleoside transport inhibitor, was administered as a 15 min i.v. infusion of 2.5 mg to eight healthy male subjects. Plasma and whole blood concentrations were measured up to 32 h post-dose, and were related to adenosine breakdown inhibition (ABI) measured ex vivo, which served as a pharmacodynamic endpoint. 2. The red blood cell/plasma distribution of draflazine was non-linear and characterized as a capacity-limited specific binding to the nucleoside transporter on the red blood cells. The binding (dissociation) constant Kd was 0.87 ng ml-1 plasma and the maximal specific binding capacity (Bmax) was 164 ng ml-1 RBC, which corresponds to about 14,000 specific binding sites per erythrocyte. Non-specific binding amounted to less than 15% of the total binding. 3. The pharmacokinetics of draflazine in blood were determined in each subject and characterized by a two-compartment pharmacokinetic model. The pharmacokinetic parameters (mean +/- s.d.) were: clearance 22.0 +/- 8.0 ml mm-1, volume of distribution at steady-state 39.8 +/- 4.7 l and terminal half-life 24.0 +/- 9.4 h. Concentrations in plasma were much lower, and could only be determined accurately in pooled plasma samples with a red blood cell binding assay. The pharmacokinetic parameters in pooled plasma were: clearance 551 ml min-1, volume of distribution at steady-state 349 l and terminal half-life 10.7 h. 4. A non-linear relationship was observed between the plasma or blood concentration of draflazine and the ABI determined ex vivo. This relationship was characterized by the sigmoidal Emax pharmacodynamic model. Based on concentrations in pooled plasma, values of the pharmacodynamic parameters were Emax 100%, IC50 10.5 ng ml-1 and Hill factor 0.9. When using whole blood concentrations, the relationship was much steeper with values (mean +/- s.d.) Emax 92.4 +/- 5.6%, IC50 76.0 +/- 15.3 ng ml-1 and Hill factor 3.5 +/- 0.9. 5. Binding to the nucleoside transporter on red blood cells is an important determinant of the pharmacokinetics of draflazine and a high degree of occupancy of the transporter by draflazine is required to inhibit adenosine breakdown ex vivo. It is suggested that red blood cell nucleoside transporter occupancy may serve as a useful pharmacodynamic endpoint in dose ranging studies with draflazine." @default.
• W2000248717 created "2016-06-24" @default.
• W2000248717 creator A5008196740 @default.
• W2000248717 creator A5013121659 @default.
• W2000248717 creator A5022136918 @default.
• W2000248717 creator A5031743563 @default.
• W2000248717 creator A5031824382 @default.
• W2000248717 creator A5033133140 @default.
• W2000248717 creator A5034023067 @default.
• W2000248717 creator A5034871005 @default.
• W2000248717 creator A5048445676 @default.
• W2000248717 creator A5058611157 @default.
• W2000248717 creator A5063535372 @default.
• W2000248717 date "1996-11-01" @default.
• W2000248717 modified "2023-09-27" @default.
• W2000248717 title "The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine" @default.
• W2000248717 cites W1969611462 @default.
• W2000248717 cites W1970391510 @default.
• W2000248717 cites W1970592808 @default.
• W2000248717 cites W1975785820 @default.
• W2000248717 cites W1976573800 @default.
• W2000248717 cites W1983649348 @default.
• W2000248717 cites W1991869406 @default.
• W2000248717 cites W1995656922 @default.
• W2000248717 cites W1997876761 @default.
• W2000248717 cites W1998746287 @default.
• W2000248717 cites W2012491715 @default.
• W2000248717 cites W2013276920 @default.
• W2000248717 cites W2014420443 @default.
• W2000248717 cites W2042074431 @default.
• W2000248717 cites W2042399844 @default.
• W2000248717 cites W2042784970 @default.
• W2000248717 cites W2062151693 @default.
• W2000248717 cites W2066342049 @default.
• W2000248717 cites W2068862347 @default.
• W2000248717 cites W2069081108 @default.
• W2000248717 cites W2069533120 @default.
• W2000248717 cites W2073199636 @default.
• W2000248717 cites W2078865702 @default.
• W2000248717 cites W2079265669 @default.
• W2000248717 cites W2083780015 @default.
• W2000248717 cites W2086032237 @default.
• W2000248717 cites W2120765078 @default.
• W2000248717 cites W2410538282 @default.
• W2000248717 cites W2414743756 @default.
• W2000248717 cites W2502670554 @default.
• W2000248717 doi "https://doi.org/10.1111/j.1365-2125.1996.tb00116.x" @default.
• W2000248717 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8951192" @default.
• W2000248717 hasPublicationYear "1996" @default.
• W2000248717 type Work @default.
• W2000248717 sameAs 2000248717 @default.
• W2000248717 citedByCount "8" @default.
• W2000248717 countsByYear W20002487172020 @default.
• W2000248717 countsByYear W20002487172021 @default.
• W2000248717 crossrefType "journal-article" @default.
• W2000248717 hasAuthorship W2000248717A5008196740 @default.
• W2000248717 hasAuthorship W2000248717A5013121659 @default.
• W2000248717 hasAuthorship W2000248717A5022136918 @default.
• W2000248717 hasAuthorship W2000248717A5031743563 @default.
• W2000248717 hasAuthorship W2000248717A5031824382 @default.
• W2000248717 hasAuthorship W2000248717A5033133140 @default.
• W2000248717 hasAuthorship W2000248717A5034023067 @default.
• W2000248717 hasAuthorship W2000248717A5034871005 @default.
• W2000248717 hasAuthorship W2000248717A5048445676 @default.
• W2000248717 hasAuthorship W2000248717A5058611157 @default.
• W2000248717 hasAuthorship W2000248717A5063535372 @default.
• W2000248717 hasBestOaLocation W20002487171 @default.
• W2000248717 hasConcept C104317684 @default.
• W2000248717 hasConcept C111113717 @default.
• W2000248717 hasConcept C112705442 @default.
• W2000248717 hasConcept C126322002 @default.
• W2000248717 hasConcept C139254425 @default.
• W2000248717 hasConcept C149011108 @default.
• W2000248717 hasConcept C1621761 @default.
• W2000248717 hasConcept C185592680 @default.
• W2000248717 hasConcept C2776543447 @default.
• W2000248717 hasConcept C2776557347 @default.
• W2000248717 hasConcept C2776575606 @default.
• W2000248717 hasConcept C2780549722 @default.
• W2000248717 hasConcept C55493867 @default.
• W2000248717 hasConcept C71924100 @default.
• W2000248717 hasConcept C98274493 @default.
• W2000248717 hasConceptScore W2000248717C104317684 @default.
• W2000248717 hasConceptScore W2000248717C111113717 @default.
• W2000248717 hasConceptScore W2000248717C112705442 @default.
• W2000248717 hasConceptScore W2000248717C126322002 @default.
• W2000248717 hasConceptScore W2000248717C139254425 @default.
• W2000248717 hasConceptScore W2000248717C149011108 @default.
• W2000248717 hasConceptScore W2000248717C1621761 @default.
• W2000248717 hasConceptScore W2000248717C185592680 @default.
• W2000248717 hasConceptScore W2000248717C2776543447 @default.
• W2000248717 hasConceptScore W2000248717C2776557347 @default.
• W2000248717 hasConceptScore W2000248717C2776575606 @default.
• W2000248717 hasConceptScore W2000248717C2780549722 @default.
• W2000248717 hasConceptScore W2000248717C55493867 @default.
• W2000248717 hasConceptScore W2000248717C71924100 @default.
• W2000248717 hasConceptScore W2000248717C98274493 @default.
• W2000248717 hasIssue "5" @default.

• next